Description

22,42,436 equity shares of Cholamandalam Investment and Finance Company Ltd allotted to QIPs pursuant to warrant conversion are listed and admitted for trading with effect from November 26, 2025.

Summary

Cholamandalam Investment and Finance Company Ltd (Scrip Code: 511243, ISIN: INE121A01024) has listed 22,42,436 equity shares of Rs. 2/- each on BSE. These shares were allotted to Qualified Institutional Placements (QIPs) pursuant to conversion of warrants issued on QIP basis. The shares rank pari-passu with existing equity shares and are admitted for trading with effect from Wednesday, November 26, 2025.

Key Points

  • 22,42,436 equity shares of face value Rs. 2/- each listed
  • Shares allotted to QIPs pursuant to warrant conversion
  • Issue price: Rs. 1,369.05 per share
  • Date of allotment: October 08, 2025
  • Distinctive numbers: 841399033 to 843641468
  • Shares rank pari-passu with existing equity shares
  • Trading commencement: November 26, 2025

Regulatory Changes

No regulatory changes introduced by this circular.

Compliance Requirements

  • Trading members are informed of the new securities listing
  • No specific compliance actions required from trading members
  • Standard trading procedures apply for the newly listed securities

Important Dates

  • Date of Allotment: October 08, 2025
  • Listing and Trading Commencement: November 26, 2025
  • Notice Date: November 25, 2025

Impact Assessment

This is a routine listing of equity shares arising from warrant conversion under the QIP route. The 22.42 lakh shares represent a small fraction of the company’s total equity base. The shares being issued at Rs. 1,369.05 per share to qualified institutional investors indicates institutional confidence. The listing is expected to have minimal impact on trading volumes or stock price as the dilution is limited and the shareholders are long-term institutional investors. The pari-passu ranking ensures equal rights with existing shareholders.

Impact Justification

Routine listing of equity shares from warrant conversion representing 0.4% dilution, limited market impact expected